CCA
VRTX icon

Catalyst Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Catalyst Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.7K Sell
82
-25
-23% -$11.1K ﹤0.01% 303
2026
Q1 		$47.8K Buy
107
+9
+9% +$4.2K ﹤0.01% 297
2025
Q4 		$44.4K Sell
98
-26
-21% -$11.2K ﹤0.01% 325
2025
Q3 		$48.6K Sell
124
-33
-21% -$13.8K ﹤0.01% 386
2025
Q2 		$69.9K Sell
157
-45
-22% -$20.7K ﹤0.01% 379
2025
Q1 		$97.9K Sell
202
-9,343
-98% -$4.35M ﹤0.01% 304
2024
Q4 		$3.84M Sell
9,545
-225
-2% -$104K 0.08% 82
2024
Q3 		$4.54M Sell
9,770
-325
-3% -$156K 0.1% 78
2024
Q2 		$4.73M Sell
10,095
-48
-0.5% -$20.8K 0.11% 69
2024
Q1 		$4.24M Sell
10,143
-174
-2% -$73.6K 0.1% 77
2023
Q4 		$4.2M Sell
10,317
-798
-7% -$295K 0.11% 73
2023
Q3 		$3.87M Sell
11,115
-327
-3% -$114K 0.11% 77
2023
Q2 		$4.03M Sell
11,442
-605
-5% -$204K 0.12% 76
2023
Q1 		$3.8M Buy
12,047
+1,022
+9% +$307K 0.12% 76
2022
Q4 		$3.18M Buy
11,025
+10,820
+5,278% +$3.3M 0.1% 88
2022
Q3 		$59K Buy
205
+2
+1% +$575 ﹤0.01% 254
2022
Q2 		$57K Buy
203
+28
+16% +$7.49K ﹤0.01% 274
2022
Q1 		$46K Buy
175
+31
+22% +$7.36K ﹤0.01% 314
2021
Q4 		$32K Sell
144
-12
-8% -$2.33K ﹤0.01% 324
2021
Q3 		$28K Sell
156
-3
-2% -$586 ﹤0.01% 328
2021
Q2 		$32K Buy
159
+5
+3% +$1.05K ﹤0.01% 335
2021
Q1 		$33K Sell
154
-29
-16% -$6.37K ﹤0.01% 299
2020
Q4 		$43K Sell
183
-28,667
-99% -$6.58M ﹤0.01% 277
2020
Q3 		$7.85M Sell
28,850
-1,850
-6% -$510K 0.44% 32
2020
Q2 		$8.91M Sell
30,700
-2,800
-8% -$759K 0.46% 28
2020
Q1 		$7.97M Buy
+33,500
New +$7.68M 0.4% 29

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Catalyst Capital Advisors's VRTX Position: Q2 2026 in Review

Catalyst Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q2 2026, selling an estimated $11.1K and leaving 82 shares worth $40.7K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

Catalyst Capital Advisors first reported a position in VRTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.91M in Q2 2020. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Catalyst Capital Advisors held 82 shares of Vertex Pharmaceuticals worth $40.7K as of Q2 2026.
  • Catalyst Capital Advisors sold 25 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.1K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Catalyst Capital Advisors's portfolio in Q2 2026, its #303 holding.
  • Catalyst Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Catalyst Capital Advisors's Vertex Pharmaceuticals position peaked at $8.91M in Q2 2020.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Catalyst Capital Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.